Publication Month: Apr 2022 | Report Code: TIPRE00009653 | No. of Pages: 178 | Category: Pharmaceuticals | Status: Published
In nonalcoholic fatty liver disease (NAFLD), fat builds up in the liver. Non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) are types of NAFLD. When the fat buildup causes inflammation and damage, it leads to the development of NASH, which can lead to scarring of the liver. The scarring of the liver is a potentially life-threatening condition called cirrhosis.
The report offers insights and in-depth analysis of the non-alcoholic steatohepatitis (NASH) market emphasizing various parameters such as market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, it includes the impact of the COVID-19 pandemic on the market across all the regions. The COVID-19 pandemic has disrupted the socioeconomic conditions of various countries across the world. In North America, the US was profoundly affected by the COVID-19 pandemic. Liver injury in the form of increased transaminases and hyperbilirubinemia among COVID-19 patients can be attributed to a couple of factors, including pre-existing liver disease. The comorbidity of nonalcoholic fatty liver disease (NAFLD) and NASH in these patients makes them prone to severe forms of liver injury. Given the high prevalence of NAFLD worldwide, it is far critical to recognize the results of COVID-19 in such patients, which include the role of comorbidities, disease progression, and COVID severity. The presence of fibrosis rather than NASH/NAFLD is associated with worse clinical outcomes and higher mortality in COVID-19 patients.
The impact of COVID-19 on comorbid patient populations, including people with diabetes, obesity, fatty liver disease, and NASH, has triggered the need of providing optimal care to patients. The Global Liver Institute is committed to operating with researchers and innovators worldwide to evaluate and inform a strong response to this pandemic rapidly. Research revolving around combating NAFLD and NASH indicates that the anticipated relationship with weight problems is stark. Therefore, a high incidence of NASH demands advanced diagnostics and treatments, which boosts research and development in the market. Thus, the COVID-19 crisis has fueled the non-alcoholic steatohepatitis (NASH) market growth.
Get more information on this report :
NASH is an under-recognized condition. For a structured referral pathway and early detection, building greater awareness of this disease among the general public and primary care physicians (PCPs) is essential. By establishing a clear patient pathway for referrals and patient awareness campaigns, more individuals can be identified and sent to specialists for further evaluation. To raise awareness of NASH, the NASH Education Program launched the public education campaign on June 12, 2018, observed as the "International NASH Day," to raise awareness about the NAFLD and its more advanced form, NASH, which affects over ~115 million people.
NASH 24X7, a digital platform aimed at raising exposure and awareness regarding the NASH epidemic, took a few steps on the International NASH Day 2019 through HCP support, patient awareness, and press/TV release programs. To raise awareness on this day, NASH Crusaders of NASH 24X7 joined with top healthcare providers (HCPs), especially gastroenterologists and hepatologists, across India to hold many small and large-scale awareness & education workshops on liver health, highlighting the necessity of a healthy lifestyle in preventing NAFLD/NASH.
On the International NASH Day 2020, the American Liver Foundation joined a global community to raise awareness about NASH with support from the Allergan Foundation. American Liver Foundation (ALF) is now piloting a NASH Text Messaging Program, wherein people can sign up to receive weekly 3 messages for 10 weeks. Messages consist of hyperlinks to NASH resources, relevant facts, interactive quizzes, and sensible pointers for daily self-management. The ALF will open this system to the general public when the pilot is finished and evaluated. It collaborated with the Global Liver Institute (GLI) on the International NASH Day, and shared a few social media posts linked to GLI posts and the International NASH day page.
Thus, rising initiatives for the propelling the awareness regarding NASH are driving the non-alcoholic steatohepatitis (NASH) market.
Based on product, the non-alcoholic steatohepatitis (NASH) market is segmented into vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc, and others. In 2021, the others segment held the largest share of the market. The selonsertib & cenicriviroc segment is expected to register the fastest CAGR of 73.3% during the forecast period.
Get more information on this report :
Based on application, the non-alcoholic steatohepatitis (NASH) market is bifurcated into treatment and diagnosis. In 2021, the treatment segment held a larger share of the market. However, the treatment segment is expected to register a higher CAGR of 47.3% during the forecast period.
Based on sales channel, the non-alcoholic steatohepatitis (NASH) market is segmented into hospital pharmacy, retail pharmacy, and online provider. In 2021, the retail pharmacy segment held the largest share of the market. Moreover, the retail pharmacies segment is expected to report the highest CAGR of 47.2% during 2021–2028.
The non-alcoholic steatohepatitis (NASH) market players adopt organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.
Based on geography, the non-alcoholic steatohepatitis (NASH) market is segmented as North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.